Duloxetine
Product Images NDC 53002-1561

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 53002-1561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Fig1

A line graph showing the proportion of patients with relapse over time in days from randomization. Two treatments are compared: Placebo and Duloxetine, with the Duloxetine curve showing a lower proportion of relapse over the period up to 200 days.*

FDA Label Image

Duloxetine Fig10

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis represents percentage of patients improved. Duloxetine shows a higher percentage of patient improvement across pain improvement levels compared to placebo.*

FDA Label Image

Duloxetine Fig2

A line graph comparing the proportion of patients with relapse over time (days) from randomization between Duloxetine and placebo treatments. The x-axis represents time from randomization to relapse (days) up to 300 days, and the y-axis shows the proportion of patients with relapse from 0 to 1. The graph has two lines: a dashed line for placebo and a solid line for Duloxetine, indicating differences in relapse rates over time.*

FDA Label Image

Duloxetine Fig3

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares duloxetine at doses of 60 mg BID, 60 mg QD, 20 mg QD, and placebo, with duloxetine groups generally showing higher percentages of patient improvement across pain improvement levels.*

FDA Label Image

Duloxetine Fig4

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The chart illustrates decreasing trends in patient improvement percentages as pain improvement increases from >0 to 100 percent.*

FDA Label Image

Duloxetine Fig5

A line graph showing the percentage of patients improved based on percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, with patient improvement percentage plotted on the vertical axis and percent improvement in pain on the horizontal axis.*

FDA Label Image

Duloxetine Fig6

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares effects of Duloxetine at doses of 20 mg, 60 mg, and 120 mg once daily, alongside a placebo. The y-axis indicates the percentage of patients improved, ranging from 0 to 100, and the x-axis shows percent improvement in pain from baseline, from greater than 0 to 100.*

FDA Label Image

Duloxetine Fig8

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo and Duloxetine 60/120 mg once daily, with Duloxetine showing higher percentages of patient improvement across increasing pain improvement thresholds.*

FDA Label Image

Duloxetine Fig9

A line chart comparing the percentage of patients improved by Percent Improvement in Pain from Baseline (BOCF) for Duloxetine 60 mg once daily versus placebo. The X-axis represents Percent Improvement in Pain from Baseline, ranging from 0 to 100 percent, and the Y-axis shows the Percentage of Patients Improved, ranging from 0 to 100 percent. Duloxetine shows higher patient improvement percentages at most pain improvement intervals compared to placebo.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, depicting its molecular framework including a naphthalene group, a thiophene ring, and the hydrochloride salt form attached to the amine group.*

FDA Label Image

Label Image (Lbl530021494)

Duloxetine 30 mg DR-Capsules packaging label from RPK Pharmaceuticals, Inc. The label states the prescription use (Rx only) and dosing instruction to take one capsule daily or as directed. It includes NDC codes, lot number, discard date, and storage information for a bottle containing 30 capsules.*

FDA Label Image

Label Image (Lbl530021561)

Duloxetine 60mg DR-Capsules label from RPK Pharmaceuticals, Inc. The label includes instructions to take one capsule daily or as directed, specifies the package contains 30 capsules, and displays the National Drug Code (NDC) along with lot numbers and expiration dates. The label also contains patient and prescriber information fields and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.